From what I can see with cpn10 there seems to be pretty profound reason to research this drug further and in larger clinical trials. There is established benefit and safety in RA and in lupus but the cohorts have been small so there is a profound reason to increase the number of people trialled. As much higher doses were safely tolerated in lupus and 3 out of 23 patients had their RA in remission with the RA trial, then could higher doses not be trialled in RA? Sales of Enbrel, Humira and Remicade globally in 2014 were $20 billion or so, and this could be a direct competitor and these all work on tumour necrosis factor.
I have been caught up in the dilution, reduction in share price, lack of finances and have been annoyed at management but a look at the broader picture and these guys are doing some pretty important and (potentially) profitable work.
IVX Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)